| 1ADS | A:1-315 | AN UNLIKELY SUGAR SUBSTRATE SITE IN THE 1.65 ANGSTROMS STRUCTURE OF THE HUMAN ALDOSE REDUCTASE HOLOENZYME IMPLICATED IN DIABETIC COMPLICATIONS |
| 1AZ1 | A:2-315 | ALRESTATIN BOUND TO C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE |
| 1AZ2 | A:2-315 | CITRATE BOUND, C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE |
| 1EF3 | A:1-315; B:1-315 | FIDARESTAT BOUND TO HUMAN ALDOSE REDUCTASE |
| 1EL3 | A:1A-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH IDD384 INHIBITOR |
| 1IEI | A:1-315 | CRYSTAL STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH THE INHIBITOR ZENARESTAT. |
| 1IHI | A:3-322; B:3-322 | CRYSTAL STRUCTURE OF HUMAN TYPE III 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE/BILE ACID BINDING PROTEIN (AKR1C2) COMPLEXED WITH NADP+ AND URSODEOXYCHOLATE |
| 1J96 | B:1-323; A:1-323 | HUMAN 3ALPHA-HSD TYPE 3 IN TERNARY COMPLEX WITH NADP AND TESTOSTERONE |
| 1MRQ | A:1-323 | CRYSTAL STRUCTURE OF HUMAN 20ALPHA-HSD IN TERNARY COMPLEX WITH NADP AND 20ALPHA-HYDROXY-PROGESTERONE |
| 1PWL | A:0-315 | CRYSTAL STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH NADP AND MINALRESTAT |
| 1PWM | A:0-315 | CRYSTAL STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH NADP AND FIDARESTAT |
| 1RY0 | A:5-323; B:5-323 | STRUCTURE OF PROSTAGLANDIN F SYNTHASE WITH PROSTAGLANDIN D2 |
| 1RY8 | A:5-323; B:5-323 | PROSTAGLANDIN F SYNTHASE COMPLEXED WITH NADPH AND RUTIN |
| 1S1P | A:6-320 | CRYSTAL STRUCTURES OF PROSTAGLANDIN D2 11-KETOREDUCTASE (AKR1C3) IN COMPLEX WITH THE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FLUFENAMIC ACID AND INDOMETHACIN |
| 1S1R | A:6-321 | CRYSTAL STRUCTURES OF PROSTAGLANDIN D2 11-KETOREDUCTASE (AKR1C3) IN COMPLEX WITH THE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FLUFENAMIC ACID AND INDOMETHACIN |
| 1S2A | A:6-320 | CRYSTAL STRUCTURES OF PROSTAGLANDIN D2 11-KETOREDUCTASE IN COMPLEX WITH THE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FLUFENAMIC ACID AND INDOMETHACIN |
| 1S2C | A:6-320 | CRYSTAL STRUCTURES OF PROSTAGLANDIN D2 11-KETOREDUCTASE IN COMPLEX WITH THE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FLUFENAMIC ACID AND INDOMETHACIN |
| 1T40 | A:1A-315 | CRYSTAL STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH NADP AND IDD552 AT PH 5 |
| 1T41 | A:1001-315 | CRYSTAL STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH NADP AND IDD552 |
| 1US0 | A:0-313 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR IDD594 AT 0.66 ANGSTROM |
| 1X96 | A:0-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE WITH CITRATES BOUND IN THE ACTIVE SITE |
| 1X97 | A:0-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH 2R4S (STEREOISOMER OF FIDARESTAT, 2S4S) |
| 1X98 | A:0-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH 2S4R (STEREOISOMER OF FIDARESTAT, 2S4S) |
| 1XF0 | A:5-323 | CRYSTAL STRUCTURE OF HUMAN 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 5 (AKR1C3) COMPLEXED WITH DELTA4-ANDROSTENE-3,17-DIONE AND NADP |
| 1XGD | A:1-315 | APO R268A HUMAN ALDOSE REDUCTASE |
| 1XJB | B:2-323; A:-1-323 | CRYSTAL STRUCTURE OF HUMAN TYPE 3 3ALPHA-HYDROXYSTEROID DEHYDROGENASE IN COMPLEX WITH NADP(H), CITRATE AND ACETATE MOLECULES |
| 1Z3N | A:0-315 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR LIDORESTAT AT 1.04 ANGSTROM |
| 1Z89 | A:0-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH NOVEL SULFONYL-PYRIDAZINONE INHIBITOR |
| 1Z8A | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH NOVEL SULFONYL-PYRIDAZINONE INHIBITOR |
| 1ZQ5 | A:5-321 | CRYSTAL STRUCTURE OF HUMAN ANDROGENIC 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 5 IN COMPLEXED WITH A POTENT INHIBITOR EM1404 |
| 1ZSX | A:-1-345 | CRYSTAL STRUCTURE OF HUMAN POTASSIUM CHANNEL KV BETA-SUBUNIT (KCNAB2) |
| 1ZUA | X:902-316 | CRYSTAL STRUCTURE OF AKR1B10 COMPLEXED WITH NADP+ AND TOLRESTAT |
| 2ACQ | A:1-315 | AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE |
| 2ACR | A:1-315 | AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE |
| 2ACS | A:2-315 | AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE |
| 2ACU | A:1-315 | TYROSINE-48 IS THE PROTON DONOR AND HISTIDINE-110 DIRECTS SUBSTRATE STEREOCHEMICAL SELECTIVITY IN THE REDUCTION REACTION OF HUMAN ALDOSE REDUCTASE: ENZYME KINETICS AND THE CRYSTAL STRUCTURE OF THE Y48H MUTANT ENZYME |
| 2AGT | A:0-315 | ALDOSE REDUCTASE MUTANT LEU 300 PRO COMPLEXED WITH FIDARESTAT |
| 2ALR | A:1-324 | ALDEHYDE REDUCTASE |
| 2BP1 | B:38-360; C:38-360; A:38-360; D:38-360 | STRUCTURE OF THE AFLATOXIN ALDEHYDE REDUCTASE IN COMPLEX WITH NADPH |
| 2CLP | I:39-360; A:38-360; B:38-360; C:38-360; D:38-360; E:38-360; F:38-360; G:38-360; H:38-360; J:38-360; K:38-360 | CRYSTAL STRUCTURE OF HUMAN AFLATOXIN B1 ALDEHYDE REDUCTASE MEMBER 3 |
| 2DUX | A:1-315 | CRYSTAL STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH ZOPOLRESTAT AFTER 3 DAYS SOAKING (3DAYS_SOAKED_1) |
| 2DUZ | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AFTER 3 DAYS SOAKING (3DAYS_SOAKED_2) |
| 2DV0 | A:2-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH ZOPOLRESTAT AFTER 6 DAYS SOAKING(6DAYS_SOAKED_2) |
| 2F2K | A:1-315 | ALDOSE REDUCTASE TERTIARY COMPLEX WITH NADPH AND DEG |
| 2F38 | A:5-323 | CRYSTAL STRUCTURE OF PROSTAGLANDIN F SYNATHASE CONTAINING BIMATOPROST |
| 2FGB | A:1-323 | CRYSTAL STRUCTURE OF HUMAN 17BET A-HYDROXYSTEROID DEHYDROGENASE TYPE 5 IN COMPLEXES WITH PEG AND NADP |
| 2FVL | A:1-323; B:1-323; C:1-323 | CRYSTAL STRUCTURE OF HUMAN 3-ALPHA HYDROXYSTEROID/DIHYDRODIOL DEHYDROGENASE (AKR1C4) COMPLEXED WITH NADP+ |
| 2FZ8 | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AT 1.48 A(1 DAY SOAKING). |
| 2FZ9 | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AFTER SIX DAYS SOAKING. |
| 2FZB | A:0-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH FOUR TOLRESTAT MOLECULES AT 1.5 A RESOLUTION. |
| 2FZD | A:0-312 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH TOLRESTAT AT 1.08 A RESOLUTION. |
| 2HDJ | A:2-323; B:2-323 | CRYSTAL STRUCTURE OF HUMAN TYPE 3 3ALPHA-HYDROXYSTEROID DEHYDROGENASE IN COMPLEX WITH NADP(H) |
| 2HV5 | A:2-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AFTER THREE DAYS SOAKING (3DAYS_SOAKED_3) |
| 2HVN | A:1-315 | HUMAN ALDOSE REDUCTASE-ZOPOLRESTAT COMPLEX OBTAINED BY COCRYSTALLISATION AFTER ONE DAY (1DAY_COCRYST) |
| 2HVO | A:1-315 | HUMAN ALDOSE REDUCTASE-ZOPOLRESTAT COMPLEX OBTAINED BY COCRYSTALLISATION (10DAYS_COCRYST) |
| 2I16 | A:1-314 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR IDD594 AT TEMPERATURE OF 15K |
| 2I17 | A:1-314 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR IDD594 AT TEMPERATURE OF 60K |
| 2IKG | A:0-315 | ALDOSE REDUCTASE COMPLEXED WITH NITROPHENYL-OXADIAZOL TYPE INHIBITOR AT 1.43 A |
| 2IKH | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH NITROFURYL-OXADIAZOL INHIBITOR AT 1.55 A |
| 2IKI | A:1-311 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH HALOGENATED IDD-TYPE INHIBITOR |
| 2IKJ | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH NITRO-SUBSTITUTED IDD-TYPE INHIBITOR |
| 2INE | A:2-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH PHENYLACETIC ACID |
| 2INZ | A:1-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH 2-HYDROXYPHENYLACETIC ACID |
| 2IPJ | A:3-323; B:3-323 | CRYSTAL STRUCTURE OF H3ALPHA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 MUTANT Y24A IN COMPLEX WITH NADP+ AND EPI-TESTOSTERONE |
| 2IPW | A:2-315 | CRYSTAL STRUCTURE OF C298A W219Y ALDOSE REDUCTASE COMPLEXED WITH DICHLOROPHENYLACETIC ACID |
| 2IQ0 | A:2-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH HEXANOIC ACID |
| 2IQD | A:1-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH LIPOIC ACID |
| 2IS7 | A:1-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH DICHLOROPHENYLACETIC ACID |
| 2ISF | A:2-315 | CRYSTAL STRUCTURE OF C298A W219Y ALDOSE REDUCTASE COMPLEXED WITH PHENYLACETIC ACID |
| 2J8T | A:0-315 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP AND CITRATE AT 0.82 ANGSTROM |
| 2NVC | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH NOVEL NAPHTHO[1,2-D]ISOTHIAZOLE ACETIC ACID DERIVATIVE (3) |
| 2NVD | A:1-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH NOVEL NAPHTHO[1,2-D]ISOTHIAZOLE ACETIC ACID DERIVATIVE (2) |
| 2PD5 | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT V47I COMPLEXED WITH ZOPOLRESTAT |
| 2PD9 | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT V47I COMPLEXED WITH FIDARESTAT. |
| 2PDB | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT F121P COMPLEXED WITH ZOPOLRESTAT. |
| 2PDC | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT F121P COMPLEXED WITH IDD393. |
| 2PDF | A:2-315 | HUMAN ALDOSE REDUCTASE MUTANT L300P COMPLEXED WITH ZOPOLRESTAT. |
| 2PDG | A:2-315 | HUMAN ALDOSE REDUCTASE WITH URACIL-TYPE INHIBITOR AT 1.42A. |
| 2PDH | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT L300P COMPLEXED WITH URACIL-TYPE INHIBITOR AT 1.45 A. |
| 2PDI | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT L300A COMPLEXED WITH ZOPOLRESTAT AT 1.55 A. |
| 2PDJ | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT L300A COMPLEXED WITH IDD393. |
| 2PDK | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT L301M COMPLEXED WITH SORBINIL. |
| 2PDL | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT L301M COMPLEXED WITH TOLRESTAT. |
| 2PDM | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT S302R COMPLEXED WITH ZOPOLRESTAT. |
| 2PDN | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT S302R COMPLEXED WITH URACIL-TYPE INHIBITOR. |
| 2PDP | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT S302R COMPLEXED WITH IDD 393. |
| 2PDQ | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT C303D COMPLEXED WITH URACIL-TYPE INHIBITOR. |
| 2PDU | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT C303D COMPLEXED WITH IDD393. |
| 2PDW | A:1-315 | HUMAN ALDOSE REDUCTASE MUTANT C303D COMPLEXED WITH FIDARESTAT. |
| 2PDX | A:1-312 | HUMAN ALDOSE REDUCTASE DOUBLE MUTANT S302R-C303D COMPLEXED WITH ZOPOLRESTAT. |
| 2PDY | A:1-315 | HUMAN ALDOSE REDUCTASE DOUBLE MUTANT S302R-C303D COMPLEXED WITH FIDARESTAT. |
| 2PEV | A:0-315 | COMPLEX OF ALDOSE REDUCTASE WITH NADP+ AND SIMALTANEOUSLY BOUND COMPETETIVE INHIBITORS FIDARESTAT AND IDD594. CONCENTRATION OF FIDARESTAT IN SOAKING SOLUTION EXCEEDS CONCENTRATION OF IDD594. |
| 2PF8 | A:0-315 | COMPLEX OF ALDOSE REDUCTASE WITH NADP+ AND SIMALTANEOUSLY BOUND COMPETETIVE INHIBITORS FIDARESTAT AND IDD594. CONCENTRATION OF FIDARESTAT IN SOAKING SOLUTION IS EQUAL TO CONCENTRATION OF IDD594. |
| 2PFH | A:0-313 | COMPLEX OF ALDOSE REDUCTASE WITH NADP+ AND SIMALTANEOUSLY BOUND COMPETETIVE INHIBITORS FIDARESTAT AND IDD594. CONCENTRATION OF FIDARESTAT IN SOAKING SOLUTION IS LESS THAN CONCENTRATION OF IDD594. |
| 2PZN | A:1001-315 | THE CRYSTALLOGRAPHIC STRUCTURE OF ALDOSE REDUCTASE IDD393 COMPLEX CONFIRMS LEU300 AS A SPECIFICITY DETERMINANT |
| 2QXW | A:0-312 | PERDEUTERATED ALR2 IN COMPLEX WITH IDD594 |
| 2R24 | A:0-315 | HUMAN ALDOSE REDUCTASE STRUCTURE |
| 3BCJ | A:0-315 | CRYSTAL STRUCTURE OF ALDOSE REDUCTASE COMPLEXED WITH 2S4R (STEREOISOMER OF FIDARESTAT, 2S4S) AT 0.78 A |
| 3BUR | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF DELTA(4)-3-KETOSTEROID 5-BETA-REDUCTASE IN COMPLEX WITH NADP AND TESTOSTERONE. RESOLUTION: 1.62 A. |
| 3BUV | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF HUMAN DELTA(4)-3-KETOSTEROID 5-BETA-REDUCTASE IN COMPLEX WITH NADP AND HEPES. RESOLUTION: 1.35 A. |
| 3BV7 | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF DELTA(4)-3-KETOSTEROID 5-BETA-REDUCTASE IN COMPLEX WITH NADP AND GLYCEROL. RESOLUTION: 1.79 A. |
| 3C3U | A:4-323 | CRYSTAL STRUCTURE OF AKR1C1 IN COMPLEX WITH NADP AND 3,5-DICHLOROSALICYLIC ACID |
| 3CAQ | B:3-326; A:2-326 | CRYSTAL STRUCTURE OF 5BETA-REDUCTASE (AKR1D1) IN COMPLEX WITH NADPH |
| 3CAS | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF 5BETA-REDUCTASE (AKR1D1) IN COMPLEX WITH NADP+ AND 4-ANDROSTENEDIONE |
| 3CAV | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF 5BETA-REDUCTASE (AKR1D1) IN COMPLEX WITH NADP+ AND 5BETA-PREGNAN-3,20-DIONE |
| 3CMF | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF HUMAN LIVER 5BETA-REDUCTASE (AKR1D1) IN COMPLEX WITH NADP AND CORTISONE. RESOLUTION 1.90 A. |
| 3COT | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF HUMAN LIVER DELTA(4)-3-KETOSTEROID 5BETA-REDUCTASE (AKR1D1) IN COMPLEX WITH PROGESTERONE AND NADP. RESOLUTION: 2.03 A. |
| 3DN5 | A:1-315 | ALDOSE REDUCTASE IN COMPLEX WITH NOVEL BIARYLIC INHIBITOR |
| 3DOP | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF 5BETA-REDUCTASE (AKR1D1) IN COMPLEX WITH NADP+ AND 5BETA-DIHYDROTESTOSTERONE, RESOLUTION 2.00A |
| 3G1R | A:2-326; B:2-326 | CRYSTAL STRUCTURE OF HUMAN LIVER 5BETA-REDUCTASE (AKR1D1) IN COMPLEX WITH NADP AND FINASTERIDE. RESOLUTION 1.70 A |
| 3G5E | A:0-315 | HUMAN ALDOSE REDUCTASE COMPLEXED WITH IDD 740 INHIBITOR |
| 3GHR | A:0-315 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR IDD594. INVESTIGATION OF GLOBAL EFFECTS OF RADIATION DAMAGE ON PROTEIN STRUCTURE. FIRST STAGE OF RADIATION DAMAGE |
| 3GHS | A:0-315 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR IDD594. INVESTIGATION OF GLOBAL EFFECTS OF RADIATION DAMAGE ON PROTEIN STRUCTURE. SECOND STAGE OF RADIATION DAMAGE. |
| 3GHT | A:0-315 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR IDD594. INVESTIGATION OF GLOBAL EFFECTS OF RADIATION DAMAGE ON PROTEIN STRUCTURE. THIRD STAGE OF RADIATION DAMAGE. |
| 3GHU | A:0-315 | HUMAN ALDOSE REDUCTASE IN COMPLEX WITH NADP+ AND THE INHIBITOR IDD594. INVESTIGATION OF GLOBAL EFFECTS OF RADIATION DAMAGE ON PROTEIN STRUCTURE. FORTH STAGE OF RADIATION DAMAGE. |
| 3GUG | A:6-323 | CRYSTAL STRUCTURE OF AKR1C1 L308V MUTANT IN COMPLEX WITH NADP AND 3,5-DICHLOROSALICYLIC ACID |
)
)